Abstract:Hyperglycemia is a hallmark characteristic of type II diabetes, due in part to increased hepatic glucose production (HGP). The gut microbiota is now recognized as an important contributor to host energy and glucose homeostasis, and our lab has demonstrated that the gut microbiota can impact HGP. One mechanism that the gut microbiome may be impact HGP is through alterations in gut-derived metabolites from breakdown of ingested foodstuff. Specifically, short chain fatty acids (SCFAs) are bacterial metabolites produced primarily in the distal intestine from dietary fibers, and when administered exogenously, SCFAs improve glucose tolerance. However, the mechanisms underlying the effects of SCFAs on glucose tolerance are not fully understood. Given that SCFAs bind to free fatty acid receptors (FFARs) 2 and 3 localized on enteroendocrine cells to induce gut peptide release, and gut peptides regulate HGP via a gut-brain-liver neuronal axis, we propose colonic SCFAs activate a neuronal signaling mechanism to lower HGP mediated via gut peptide signaling. We infused SCFAs into the colon (50min at 0.01mL/min) during a basal insulin euglycemic clamp in rats. Compared with saline infusion, colonic administration of 10mM butyrate increased the glucose infusion rate needed to maintain glycemia due to a reduction in HGP. This was associated with increased portal concentrations of GLP-1 following butyrate infusion compared to saline. We investigated the role of colonic FFAR2 signaling, which is known to induce release of GLP-1, through either co-administration of a FFAR2 antagonist with butyrate or by colon-specific FFAR2 lentiviral knockdown; both abolished the HGP-lowering effect. Next, co-administering a GLP-1 receptor antagonist with 10mM butyrate during a clamp abolished the butyrate-induced reduction of HGP. Additionally, hepatic or celiac branch vagotomy abolished the HGP-lowering effect of colonic butyrate, suggesting a celiac afferent and hepatic efferent neuronal signaling pathway. Together, these studies uncover a FFAR2, GLP-1 receptor, vagal-dependent signaling mechanism by which colonic butyrate lowers HGP. Research presented was supported under NIH award R01DK121804. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Leuconostoc mesenteroides fermentation produces butyric acid and mediates Ffar2 to regulate blood glucose and insulin in type 1 diabetic mice

Mouse Abdominal Fat Depots Reduced by Butyric Acid-Producing Leuconostoc mesenteroides

Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice

Evaluation of probiotics for improving and regulation metabolism relevant to type 2 diabetes <i>in vitro</i>

Fermented Maillard Reaction Products by Lactobacillus gasseri 4M13 Alters the Intestinal Microbiota and Improves Dysfunction in Type 2 Diabetic Mice with Colitis

Effects of Bifidobacterium BL21 and Lacticaseibacillus LRa05 on gut microbiota in type 2 diabetes mellitus mice

Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice

Antidiabetic Function of Lactobacillus fermentum MF423-Fermented Rice Bran and Its Effect on Gut Microbiota Structure in Type 2 Diabetic Mice

A Single Strain of Lactobacillus (CGMCC 21661) Exhibits Stable Glucose- and Lipid-Lowering Effects by Regulating Gut Microbiota

Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice

Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice

The Effect of Bifidobacterium animalis subsp. lactis MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice

Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice

Fermented dietary fiber from soy sauce residue exerts antidiabetic effects through regulating the PI3K/AKT signaling pathway and gut microbiota-SCFAs-GPRs axis in type 2 diabetic mellitus mice

Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice

Effects of short-chain fatty acids on blood glucose and lipid levels in mouse models of diabetes mellitus: A systematic review and network meta-analysis

Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice

Protective role of butyrate in obesity and diabetes: New insights

Colonic butyrate lowers hepatic glucose production via FFAR2-dependant GLP-1 receptor neuronal signaling

Lactobacillus fermentum MCC2759 and MCC2760 Alleviate Inflammation and Intestinal Function in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats

Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes